Increasing Immunotherapy Options for Rare Skin Cancer
The FDA approval of pembrolizumab for treating certain patients with Merkel cell carcinoma makes it the second immunotherapeutic approved...
Progress Against Cancer
The FDA approval of pembrolizumab for treating certain patients with Merkel cell carcinoma makes it the second immunotherapeutic approved...
The FDA approval of gilteritinib provides a new treatment option for certain patients whose acute myeloid leukemia tests positive...
The FDA approval makes larotrectinib the first molecularly targeted therapeutic approved for use based on a tumor biomarker rather...
The FDA recently approved two molecularly targeted therapeutics for treating patients newly diagnosed with acute myeloid leukemia (AML) who...
The FDA approval of pembrolizumab for treating certain patients with liver cancer makes it the second immunotherapeutic approved for...
The U.S. Food and Drug Administration adds a fifth molecularly targeted therapeutic option for the treatment of ALK-positive lung...
The FDA approval of talazoparib means there are now two PARP inhibitors that can be used to treat patients...
The FDA adds a fifth molecularly targeted therapeutic option for the treatment of lung cancer driven by EGFR mutations....
The FDA has approved a new molecularly targeted therapeutic called duvelisib for treating certain patients with blood cancer. The...
The FDA decision makes cemiplimab-rwlc the first-ever treatment approved specifically for treating squamous cell carcinoma. The U.S. Food and...